NHS Ayrshire & Arran Formulary Bulletin - NHS Ayrshire and Arran.

More documents

Recommendations

Info

Medicines under review by Area Drug & Therapeutics Committee (ADTC) NHS Ayrshire and Arran – Area Drug and Therapeutics Committee The medicines listed below are still being considered by the ADTC. A final decision will be communicated in the near future but in the meantime they are excluded from the NHS Ayrshire & Arran formulary Dalteparin sodium injection (Fragmin ® ) – extended treatment of symptomatic venous thromboembolism and prevention of its recurrence in patients with solid tumour (SMC 683/11) Urokinase (Syner-KINASE ® ) – lysis of blood clots Antimicrobial Management Team NHS Ayrshire and Arran – Antimicrobial Management Team (AMT) The medicines listed below are still being considered by the AMT. A final decision will be communicated in the near future but in the meantime they are excluded from the NHS Ayrshire & Arran formulary Moxifloxacin injection (Avelox ® ) – community acquired pneumonia (SMC 650/10) Temocillin (Negaban ® ) inj. – treatment of septicaemia, urinary tract and lower respiratory tract infections Medicines under review by the Formulary Management Group NHS Ayrshire and Arran – Formulary Management Group (FMG) The medicines listed below have been considered by the ADTC and their formulary status is currently being reviewed by the FMG. A final decision will be communicated in the near future but in the meantime they are excluded from the NHS Ayrshire & Arran formulary. Alteplase (Actilyse Cathflo®) injection – thrombolytic treatment of occluded central venous access devices (SMC 717/11) Atazanavir (Reyataz ® ) capsules - HIV adults (SMC 520/08), children (SMC 656/10) Atomoxetine (Strattera ® ) capsules – ADHD (children ≥6 years & adolescents (SMC 153/05) Botulinum toxin type A injection (Botox ® ) – focal spasticity associated with stroke (SMC 80/03) Brinzolamide/timolol (Azarga ® ) eye drop- open-angle glaucoma or ocular hypertension (SMC 568/09) Capecitabine (Xeloda®) tablets - adjuvant treatment of stage III (Dukes stage C) colon cancer in combination with oxaliplatin (SMC 716/11) Darunavir (Prezista ® ) tablets – HIV infection in antiretroviral naïve adults.(SMC 566/09), highly pretreated children and adolescents (SMC 604/10), HIV in antiretroviral therapy experienced adults (SMC 707/11) Denosumab injection (Prolia ® ) – osteoporosis in postmenopausal women (SMC 651/10) Enoxaparin (Clexane ® ) syringes/ multidose vials – treatment of STEMI (SMC 380/07) Etravirine (Intelence ® ) tablets – HIV (SMC 530/09) Fentanyl (Instanyl ® ) nasal spray – breakthrough pain in adults on maintenance opioid therapy for chronic cancer pain. (SMC 579/09) Fentanyl (PecFent ® ) nasal spray – breakthrough pain in adults on maintenance opioid therapy for chronic cancer pain. (SMC 663/10) Ferric carboxymaltose (Ferinject ® ) - iron deficiency anaemia (haemodialysis pts excluded) (SMC 463/08) Fosamprenavir (Telzir ® ) suspension and tablets (SMC 431/07) Fosaprepitant dimeglumine infusion (IVEmend ® ) - prevention of acute and delayed nausea and vomiting associated with cisplatin-based chemotherapy (SMC 678/11) Iron isomaltoside 1000 (Monofer ® ) – iron deficiency anaemia (haemodialysis pts excluded) (SMC 697/11) Lamivudine/zidovudine (Combivir ® ) – HIV-1 in paediatric patients (SMC 569/09) Methylphenidate (Equasym XL ® & Medikinet XL ® brands) – ADHD (SMC 99/04 and 388/07) Prasugrel (Efient ® ) tablets – prevention of atherothrombotic events in patients with ACS or STEMI undergoing or delayed PCI (SMC 562/09) Prilocaine hydrochloride (Priloketal ® ) hyperbaric solution – spinal anaesthesia (SMC 665/10) Raltegravir tablets (Isentress ® ) – HIV in adults (SMC 613/10) Sildenafil citrate injection (Revatio ® ) – pulmonary arterial hypertension (SMC 688/11) Tacrolimus ointment – maintenance in atopic eczema in children (SMC 608/10) and adults (SMC 609/10) Tenofovir disoproxil tablet (Viread ®) chronic hepatitis B (SMC 720/10) Tipranavir (Aptivus ® ) -HIV-1 infection oral solution (SMC 602/10), soft capsules (SMC 616/10) NHS Ayrshire & Arran Formulary Bulletin, Medicines Utilisation Unit August & September 2011 Page 6 of 8
Medicines under review by the Medicines Resource Group NHS Ayrshire & Arran: Medicines Resource Group (MRG) The medicines listed below have been considered by the ADTC and are currently being considered by the MRG. Recurring funding has not yet been identified for the medicine and a final decision on their formulary status has not been made by the MRG. However the medicines listed below may be requested on a case by case basis, according to SMC access criteria. Requests should be sent to the Director of Pharmacy for consideration. Where it is intended to use the medicines out with SMC access criteria an exceptional case application must be completed and sent to the Medical Director for consideration. Most relevant to Primary Care: • None Most relevant to Secondary Care: • Azacitidine injection (Vidaza®) - treatment of adult patients who are not eligible for haematopoietic stem cell transplantation with; intermediate-2 and high-risk myelodysplastic syndrome, chronic myelomonocytic leukaemia or acute myeloid leukaemia (SMC 589/09) • Bendamustine hydrochloride infusion (Levact ® ) – first-line treatment of chronic lymphocytic leukaemia (Binet stage B or C) in patients fludarabine combination chemotherapy is not appropriate (SMC 694/11) • Betaine anhydrous oral powder (Cystadane ® ) - adjunctive treatment of homocystinuria involving deficiencies or defects in cystathionine beta-synthase, 5,10-methylene-tetrahydrofolate reductase or cobalamin cofactor metabolism (SMC 407/07) • Dabigatran etexilate capsules (Pradaxa ® ) - prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (SMC 672/11) • Etanercept (Enbrel ® ) – chronic severe plaque psoriasis in children and adolescents (SMC 570/09) • Febuxostat tablets (Adenuric ® ) – chronic hyperuricaemia (SMC 637/10) • Mifamurtide infusion (Mepact®) - in combination with post-operative multi-agent chemotherapy for the treatment of high-grade resectable non-metastatic osteosarcoma (SMC 621/10) • Nilotinib capsules (Tasigna®) – treatment of adults with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukaemia in the chronic phase (SMC 709/11) • Pazopanib tablets (Votrient ® ) – first line treatment of advanced renal cell carcinoma (SMC 676/11) • Rituximab infusion (MabThera ® ) – maintenance therapy in patients with follicular lymphoma responding to induction therapy (SMC 675/11) • Sunitinib capsules (Sutent ® ) – unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression (SMC 698/11) • Ticagrelor tablets (Brilique ® ) - prevention of atherothrombotic events in adults with acute coronary syndromes (unstable angina, non ST elevation myocardial infarction or ST elevation myocardial infarction) (SMC 699/11) SMC approved medicines available on a Case by case or Exceptional case basis in NHS Ayrshire & Arran Full updated lists of all the medicines which are available within NHS Ayrshire & Arran on a case by case basis according to SMC criteria or on an exceptional case basis can be located on the Joint Formulary website, located on the NHS Ayrshire & Arran intranet. These can be accessed via “Bulletin downloads and Area Drug & Therapeutics Committee minutes “, then click on “managed entry of new drugs”. For further information please refer to the SMC website www.scottishmedicines.org Scottish Medicines Consortium – Medicines “Not Recommended for Use” A full updated list of medicines which are not recommended for use within NHS Scotland for specific indications can be located on the Joint Formulary website, located on the NHS Ayrshire & Arran intranet. These can be accessed via “Bulletin downloads and Area Drug & Therapeutics Committee minutes “, then click on “managed entry of new drugs”. For access to these medicines an exceptional case application must be completed and sent to the Medical Director for consideration. For further information please refer to the SMC website www.scottishmedicines.org NHS Ayrshire & Arran Formulary Bulletin, Medicines Utilisation Unit August & September 2011 Page 7 of 8
Page 1 and 2: Area Drug & Therapeutics Committee
Page 3 and 4: The following products have been re
Page 5: The following products have not bee

NHS Ayrshire & Arran Formulary Bulletin - NHS Ayrshire and Arran.

Create successful ePaper yourself

Delete template?

Save as template?